Ibrutinib clinical trials
Also written Imbruvica, PCI-32765 and CRA-032765.
How each study uses ibrutinib is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the ibrutinib studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- 13 Nov 2013 · IMBRUVICA · NDA 205552 (FDA, Drugs@FDA)
- European Union
- 21 Oct 2014 · Imbruvica · EMEA/H/C/003791 (EMA)
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
264 studies that test it; most in 2016 (47)
| Year | Studies |
|---|---|
| 2009 | 1 |
| 2010 | 3 |
| 2011 | 3 |
| 2012 | 16 |
| 2013 | 21 |
| 2014 | 21 |
| 2015 | 27 |
| 2016 | 47 |
| 2017 | 24 |
| 2018 | 24 |
| 2019 | 24 |
| 2020 | 22 |
| 2021 | 9 |
| 2022 | 6 |
| 2023 | 4 |
| 2024 | 4 |
| 2025 | 6 |
| 2026 | 2 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 78 · Other 186
Janssen Research & Development, LLC (30) · Pharmacyclics LLC. (28) · M.D. Anderson Cancer Center (23) · National Cancer Institute (NCI) (20) · Mayo Clinic (8) · Memorial Sloan Kettering Cancer Center (8) · Dana-Farber Cancer Institute (6) · Janssen Pharmaceutical K.K. (5)
Often tested with
Tested in the same studies.
Rituximab (37) · Venetoclax (28) · Lenalidomide (19) · Obinutuzumab (19) · Nivolumab (10) · Bortezomib (7) · Prednisone (6) · Dexamethasone (6)
Related medicines
As reviewed, each with the page that says it.
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Tested against it · 5 phase 3 studies under way
Ibrutinib is the comparator. A study of two new drugs counts under both.
- 2Pirtobrutinib · Loxo Oncology, Inc. · next primary completion Oct 2027
- 1Acalabrutinib · Acerta Pharma BV
- 1ARQ531 · Merck Sharp & Dohme LLC · next primary completion Sep 2032
- 1Rocbrutinib · Guangzhou Lupeng Pharmaceutical Company LTD. · next primary completion May 2031
Reaching primary completion within a year · 21, 2 in phase 3
Studies that test ibrutinib, phase 3 first.
- Dec 2026A Long-term Extension Study of PCI-32765 (Ibrutinib)Phase 3 · Janssen Research & Development, LLC
- Sep 2027Ibrutinib Monotherapy Versus Fixed-duration Venetoclax Plus Obinutuzumab Versus Fixed-duration Ibrutinib Plus Venetoclax in Patients With Previously Untreated Chronic Lymphocytic Leukaemia (CLL)Phase 3 · German CLL Study Group
- Dec 2026Rituxan/Bendamustine/PCI-32765 in Relapsed DLBCL, MCL, or Indolent Non-Hodgkin's LymphomaPhase 1 · Kami Maddocks, MD
- Dec 2026Pembrolizumab, Ibrutinib and Rituximab in PCNSLPhase 1/2 · Dana-Farber Cancer Institute
- Dec 2026Novel Combination Therapy in the Treatment of Relapsed and Refractory Aggressive B-Cell LymphomaPhase 2 · Canadian Cancer Trials Group
- Dec 2026Venetoclax and Ibrutinib in Treating in Participants With Chronic Lymphocytic Leukemia and Ibrutinib Resistance MutationsPhase 2 · Ohio State University Comprehensive Cancer Center
- Feb 2027MACE and BTK InhibitorsPhase 4 · University Hospital, Caen
- Feb 2027Ibrutinib and Nivolumab in Treating Patients With Relapsed or Refractory Classical Hodgkin LymphomaPhase 2 · Ohio State University Comprehensive Cancer Center
- Mar 2027Ibrutinib, Rituximab, Venetoclax, and Combination Chemotherapy in Treating Patients With Newly Diagnosed Mantle Cell LymphomaPhase 2 · M.D. Anderson Cancer Center
- Apr 2027Study to Evaluate the Safety and Preliminary Efficacy of Ibrutinib and Pembrolizumab in Patients With Chronic Lymphocytic Leukemia (CLL) or Mantle Cell Lymphoma (MCL)Phase 1/2 · Joshua Brody
Studies
Open first, then newest update. How each study uses ibrutinib is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 264
- Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (ViPOR) in Relapsed/Refractory B-cell LymphomaRecruitingPhase 1/2National Cancer Institute (NCI)NCT03223610Written as Ibrutinib
- Testing the Effectiveness of a Combination Targeted Therapy (ViPOR) for Patients With Relapsed and/or Refractory Aggressive B-cell LymphomaRecruitingPhase 2National Cancer Institute (NCI)NCT06649812Written as Ibrutinib
- MACE and BTK InhibitorsNot yet recruitingPhase 4University Hospital, CaenNCT07923162Written as ibrutinib
- Ibrutinib Combination Therapy in Transplant Ineligible Individuals With Newly Diagnosed Primary CNS LymphomaRecruitingPhase 2Canadian Cancer Trials GroupNCT05998642Written as Ibrutinib
- A Rollover Study for Continued Study Treatment and Ongoing Safety MonitoringEnrolling by invitationPhase 1Janssen Research & Development, LLCNCT06788509Written as JNJ-54179060
- Pembrolizumab, Ibrutinib and Rituximab in PCNSLRecruitingPhase 1/2Dana-Farber Cancer InstituteNCT04421560Written as Ibrutinib
- Epcoritamab Plus Ibrutinib for the Treatment of Relapsed or Refractory Aggressive B-Cell Non-Hodgkin LymphomaRecruitingPhase 1/2Yazeed SawalhaNCT06536049Written as Ibrutinib
- Epcoritamab Plus Venetoclax Plus Ibrutinib in Patients With Chronic Lymphocytic Leukemia With TP53 AlterationsNot yet recruitingPhase 2The Lymphoma Academic Research OrganisationNCT07738887Written as Ibrutinib Oral Tablet
- A Study of Epcoritamab and Ibrutinib in People With Central Nervous System Lymphoma (CNSL)RecruitingPhase 1Memorial Sloan Kettering Cancer CenterNCT07082868Written as ibrutinib
- Glofitamab Plus Ibrutinib With Obinutuzumab for the Treatment of Patients With Mantle Cell Lymphoma, IGNITE MCL TrialRecruitingPhase 1/2OHSU Knight Cancer InstituteNCT06357676Written as Ibrutinib
- Venetoclax as Consolidation in CLL Patients Treated With BTK Inhibitor MonotherapyRecruitingPhase 2The First Affiliated Hospital with Nanjing Medical UniversityNCT06958705Written as Venetoclax combined with Ibrutinib
- Ibrutinib Followed by BR (Bendamustine and Rituximab) as a Time-Limited Therapy for Waldenström MacroglobulinemiaNot yet recruitingPhase 1Institute of Hematology & Blood Diseases Hospital, ChinaNCT07169565Written as Ibrutinib
- Rituximab and Ibrutinib (RI) Versus Dexamethasone, Rituximab and Cyclophosphamide (DRC) as Initial Therapy for Waldenström's MacroglobulinaemiaRecruitingPhase 2/3University College, LondonNCT04061512Written as Rituximab, ibrutinib
- Ibrutinib for the Treatment of AIHA in Patients With CLL/SLL or CLL-like MBLRecruitingPhase 2Gruppo Italiano Malattie EMatologiche dell'AdultoNCT05694312Written as Ibrutinib 420 mg
- Venetoclax, Rituximab and Ibrutinib in TN Patients With CLL Undetectable Minimal Residual Disease (uMRD) in Treatment-naïve Patients With Chronic Lymphocytic Leukemia (CLL)RecruitingPhase 2Paolo GhiaNCT04758975Written as Ibrutinib
- Ibrutinib Combined With Rituximab for Treatment of Relapsed Refractory MYD88 and CD79A/B (or CD79B Alone) DLBCL Who Have Received at Least Two Prior TherapiesNot yet recruitingPhase 2Chinese Academy of Medical SciencesNCT04994626Written as Ibrutinib Combined With Rituximab
- R-EPOCH in Combination With Ibrutinib for Patients With Classical RT of CLLNot yet recruitingPhase 2Institute of Hematology & Blood Diseases Hospital, ChinaNCT04992377Written as R-EPOCH in Combination With Ibrutinib
- A Trial to Compare Ibrutinib Versus Lenalidomide in Combination With MRE-chemotherapy for Adult Patients With Recurrent/Refractory Primary Central Nervous System Lymphoma (PCNSL)RecruitingPhase 2Second Affiliated Hospital, School of Medicine, Zhejiang UniversityNCT04129710Written as Ibrutinib
- A Pilot Study on Intermittent Ibrutinib in Patients With Advanced-phase Chronic Lymphocytic Leukemia (CLL)RecruitingPhase 1/2Jeanette LundinNCT04771507Written as Ibrutinib
- A Prospective Multicenter Phase 2 Study of FCR/BR Alternating With Ibrutinib in Treatment-naive Patients With CLLRecruitingPhase 2Institute of Hematology & Blood Diseases Hospital, ChinaNCT03980002Written as FCR and Ibrutinib
See all 264 studies that test ibrutinib →
Given beside what is tested · 63 — ibrutinib is usual care or a partner of the new treatment
- Chemo-immunotherapy Using Ibrutinib Plus Indoximod for Patients With Pediatric Brain CancerRecruitingPhase 1Theodore S. JohnsonNCT05106296Written as Ibrutinib
- A Randomized Phase II Study Of Bruton Tyrosine Kinase Inhibitor With Or Without Venetoclax In Veterans With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)RecruitingPhase 2VA Office of Research and DevelopmentNCT06520098Written as Ibrutinib, Acalabrutinib, Zanubrutinib
- CA-4948-101: Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Relapsed or Refractory Primary Central Nervous System Lymphoma (R/R PCNSL)RecruitingPhase 1/2Curis, Inc.NCT03328078Written as Ibrutinib
- Mosunetuzumab for CLL MRD ClearanceRecruitingPhase 1/2Inhye AhnNCT07052695Written as Ibrutinib
- Study of APG2575 Single Agent and Combination Therapy in Patients With Relapsed/Refractory CLL/SLLRecruitingPhase 1/2Ascentage Pharma Group Inc.NCT04494503Written as Ibrutinib
- CAR-T-cell Treatment for Untreated High Risk MANtle Cell LymphomaRecruitingPhase 2Christian Schmidt, MDNCT06482684Written as Ibrutinib
- Testing the Addition of a New Anti-cancer Drug, Venetoclax, to the Usual Treatment (Ibrutinib and Obinutuzumab) in Untreated, Older Patients With Chronic Lymphocytic LeukemiaActive, not recruitingPhase 3National Cancer Institute (NCI)NCT03737981Written as Ibrutinib
- Assessing the Ability of Combination Treatment With Venetoclax to Permit Time Limited Therapy in Chronic Lymphocytic LeukemiaActive, not recruitingPhase 3National Cancer Institute (NCI)NCT03701282Written as Ibrutinib
- Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid in Combination With Polatuzumab (ViPOR-P) in Relapsed/Refractory B-cell LymphomaActive, not recruitingPhase 1National Cancer Institute (NCI)NCT04739813Written as Ibrutinib
- ACY-1215 in Combination With BCR Pathway Inhibitors in Relapsed CLLCompletedPhase 1Dana-Farber Cancer InstituteNCT02787369Written as Ibrutinib
- Avelumab, Utomilumab, Rituximab, Ibrutinib, and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma or Mantle Cell LymphomaCompletedPhase 1City of Hope Medical CenterNCT03440567Written as Ibrutinib
- Phase 1 Study of Ibrutinib and Immuno-Chemotherapy Using Temozolomide, Etoposide, Doxil, Dexamethasone, Ibrutinib,Rituximab (TEDDI-R) in Primary CNS LymphomaActive, not recruitingPhase 1National Cancer Institute (NCI)NCT02203526Written as Ibrutinib (Arms 2, 3 and 4)
- A Trial of Obinutuzumab,GDC-0199 Plus Ibrutinib in Relapsed/Refractory Mantle Cell Lymphoma PatientsCompletedPhase 1/2Nantes University HospitalNCT02558816Written as Ibrutinib + GA101 +GDC-0199
- Venetoclax With Ibrutinib or Acalabrutinib in Pts. With High-risk CLLActive, not recruitingPhase 2M.D. Anderson Cancer CenterNCT03128879Written as Ibrutinib
- A Study of Ibrutinib With Rituximab in People With Untreated Marginal Zone LymphomaActive, not recruitingPhase 3Memorial Sloan Kettering Cancer CenterNCT04212013Written as Ibrutinib
- A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab in Combination With Oral and Intravenous Anti-Neoplastic Agents in Adult Participants With Non-Hodgkin LymphomaActive, not recruitingPhase 2GenmabNCT05283720Written as Ibrutinib
- Rollover Study to Provide Continued Treatment for Participants With B-Cell Malignancies Previously Enrolled in Studies of Parsaclisib (INCB050465)Active, not recruitingPhase 2Incyte CorporationNCT04509700Written as parsaclisib + ibrutinib
- Bcl-2 Inhibitor GDC-0199 in Combination With Obinutuzumab and Ibrutinib in Treating Patients With Relapsed, Refractory, or Previously Untreated Chronic Lymphocytic LeukemiaActive, not recruitingPhase 1/2Kerry RogersNCT02427451Written as Ibrutinib
- Trial of Ibrutinib Combined With Nivolumab or Cetuximab to Treat Recurrent/Metastatic HNSCCTerminatedPhase 2University of California, San DiegoNCT03646461Written as Ibrutinib 560mg PO daily (Imbruvica)
- Ibrutinib, Fludarabine, and Pembrolizumab in High-Risk or Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic LymphomaCompletedPhase 2National Heart, Lung, and Blood Institute (NHLBI)NCT03204188Written as Ibrutinib
Showing 20 of 63.
As the comparator · 10 — what is tested is compared with ibrutinib
- Testing the Combination of Venetoclax and Rituximab, in Comparison to the Usual Treatment (Ibrutinib Plus Rituximab or Zanubrutinib Alone) for Waldenstrom's Macroglobulinemia/Lymphoplasmacytic LymphomaRecruitingPhase 2National Cancer Institute (NCI)NCT04840602Written as Ibrutinib
- A Study of Nemtabrutinib (MK-1026) Versus Comparator (Investigator's Choice of Ibrutinib or Acalabrutinib) in First Line (1L) Chronic Lymphocytic Leukemia (CLL)/ Small Lymphocytic Lymphoma (SLL) (MK-1026-011/BELLWAVE-011)RecruitingPhase 3Merck Sharp & Dohme LLCNCT06136559Written as Ibrutinib
- A Study of Pirtobrutinib (LOXO-305) Versus Ibrutinib in Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)RecruitingPhase 3Loxo Oncology, Inc.NCT05254743Written as Ibrutinib
- A Study of Rocbrutinib Versus Investigator's Choice of BTK Inhibitors in Patients With Relapsed or Refractory Mantle Cell LymphomaRecruitingPhase 3Guangzhou Lupeng Pharmaceutical Company LTD.NCT07377578Written as Ibrutinib
- Study of BTK Inhibitor LOXO-305 Versus Approved BTK Inhibitor Drugs in Patients With Mantle Cell Lymphoma (MCL)Active, not recruitingPhase 3Loxo Oncology, Inc.NCT04662255Written as Ibrutinib
- Study of Acalabrutinib (ACP-196) Versus Ibrutinib in Previously Treated Participants With High Risk Chronic Lymphocytic Leukemia (CLL)Active, not recruitingPhase 3Acerta Pharma BVNCT02477696Written as Ibrutinib
- A Study of Ruxolitinib vs Best Available Therapy (BAT) in Patients With Steroid-refractory Chronic Graft vs. Host Disease (GvHD) After Bone Marrow Transplantation (REACH3)CompletedPhase 3Incyte CorporationNCT03112603Written as Ibrutinib
- A Study of Zanubrutinib (BGB-3111) Versus Ibrutinib in Participants With Relapsed/Refractory Chronic Lymphocytic LeukemiaCompletedPhase 3BeiGeneNCT03734016Written as Ibrutinib
- A Study of Cirmtuzumab and Ibrutinib in Patients With B-Cell Lymphoid MalignanciesCompletedPhase 1/2Oncternal Therapeutics, IncNCT03088878Written as Cirmtuzumab (2-16 kg/mg) plus Ibrutinib
- A Study of Acalabrutinib in Combination With Rituximab Versus Ibrutinib Versus Acalabrutinib in Subjects With Relapsed or Refractory Mantle Cell LymphomaWithdrawnPhase 3Acerta Pharma BVNCT02735876Written as ibrutinib
What changed recently
From the registry's own updates since Oct 18, 2026.
Results posted1
Newly registered1
- MACE and BTK InhibitorsNov 6, 2026NCT07923162
Codes
What other systems call ibrutinib · ClinicalTrials.gg INT005692
- MeSH (NLM) C551803ibrutinibConfirmed ClinicalTrials.gov, NLM
- UNII (FDA) 1X70OSD4VXIBRUTINIBConfirmed FDA, NLM, Wikidata
- RxNorm 1442981Confirmed FDA, Wikidata
- Wikidata Q5984881ibrutinibConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C81934IbrutinibOne source FDA
- DrugBank DB09053One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C551803 | ibrutinib | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | 1X70OSD4VX | IBRUTINIB | Confirmed FDA, NLM, Wikidata |
| RxNorm | 1442981 | — | Confirmed FDA, Wikidata |
| Wikidata | Q5984881 | ibrutinib | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C81934 | Ibrutinib | One source FDA |
| DrugBank | DB09053 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.